Zoledronic Acid Dosing Interval for Metastatic Cancer Reply

被引：2
|
作者：
Himelstein, Andrew L. [1 ]
Loprinzi, Charles L. [2 ]
Shapiro, Charles L. [3 ]
机构：
[1] Helen F Graham Canc Ctr & Res Inst, 4701 Ogletown Stanton Rd,Ste 3400, Newark, DE 19713 USA
[2] Mayo Clin, Rochester, MN USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2017年 / 317卷 / 14期
关键词：
BONE METASTASES;
D O I：
10.1001/jama.2017.2566
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1478 / 1478
页数：1
相关论文
共 50 条
  • [1] Zoledronic Acid Dosing Interval for Metastatic Cancer
    Tucci, Marcello
    Buttigliero, Consuelo
    Di Maio, Massimo
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (14): : 1477 - 1478
  • [2] Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer Reply
    Hortobagyi, Gabriel N.
    Zheng, Ming
    JAMA ONCOLOGY, 2018, 4 (04) : 586 - 586
  • [3] Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer
    Shapiro, Charles L.
    Himelstein, Andrew L.
    JAMA ONCOLOGY, 2018, 4 (04) : 585 - 586
  • [4] CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer
    Himelstein, Andrew Louis
    Qin, Rui
    Novotny, Paul J.
    Seisler, Drew K.
    Khatcheressian, James L.
    Roberts, John D.
    Grubbs, Stephen S.
    O'Connor, Tracey
    Weckstein, Douglas
    Loprinzi, Charles L.
    Shapiro, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Zoledronic acid in the treatment of metastatic breast cancer
    Lluch, Ana
    Cueva, Juan
    Ruiz-Borrego, Manuel
    Ponce, Jose
    Perez-Fidalgo, Jose-Alejandro
    ANTI-CANCER DRUGS, 2014, 25 (01) : 1 - 7
  • [6] Dosing of zoledronic acid throughout the treatment continuum in breast cancer
    Hadji, Peyman
    Gnant, Michael
    Aapro, Matti
    Lipton, Allan
    Coleman, Robert
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 79 (02) : 175 - 188
  • [7] Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer
    Soe, Kent
    Delaisse, Jean-Marie
    Jakobsen, Erik H.
    Hansen, Charlotte T.
    Plesner, Torben
    ACTA ONCOLOGICA, 2014, 53 (04) : 547 - 556
  • [8] Zoledronic acid palliation in bone-metastatic breast cancer
    Furlow, Bryant
    LANCET ONCOLOGY, 2006, 7 (11): : 894 - 894
  • [9] EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE
    Tonini, G.
    Loupakis, F.
    Berardi, R.
    Badalamenti, G.
    Addeo, R.
    Ortega, C.
    Sabbatini, R.
    Vendititi, O.
    Virzi, V.
    Santini, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 203 - 203
  • [10] Effectiveness and tolerability of zoledronic acid in the treatment of metastatic prostate cancer
    Cozar, Olmo J. M.
    Carballido, Rodriguez J.
    Luque, Galvez P.
    Tabernero, Gomez A. G.
    Barreiro, Mouro A.
    Sanchez, Sanchez E.
    Gonzalez, Enguita C.
    Alcover, Garcia J.
    Garcia-Galisteo, E.
    Abascal, Garcia J. M.
    Sanchez, Chapado M.
    GomezVeiga, F.
    Minguez, Martinez R. J.
    Rodriguez, Antolin A.
    Medina, Lopez R. A.
    Rico, Morales M.
    Regadera, Sejas F. J.
    Bucar, Terrades S.
    Jamardo, Gonzalez D.
    Galvez, R.
    ACTAS UROLOGICAS ESPANOLAS, 2008, 32 (05): : 492 - 501
12345